Abstract: Disclosed herein are products, methods, and uses for a new gene therapy for treating, ameliorating, delaying the progression of, and/or preventing a muscular dystrophy involving a mutation amenable to DNA repair including, but not limited to, any mutation involving, surrounding, or affecting various regions of the DMD gene. Specifically, the disclosure provides products and methods for fixing diverse DMD mutations by replacement of large segments of the DMD gene comprising multiple exons, using CRISPR/Cas9 and Homology-Independent Targeted-Integration (HITI) to accomplish high efficiency knock-in or make large replacements using the non-homologous end-joining (NHEJ) DNA repair pathway, previously not achievable. In particular, the disclosure provides products, methods and uses for the replacement of DMD exons 1-19, 2-19, or 41-55.

Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.

Abstract: The disclosure relates to the field of gene therapy for the treatment of a muscular dystrophy including, but not limited to, Duchenne Muscular Dystrophy (DMD). More particularly, the disclosure provides nucleic acids, including nucleic acids encoding U7-based small nuclear ribonucleic acids (RNAs) (snRNAs), U7-based snRNAs, and recombinant adeno-associated virus (rAAV) comprising the nucleic acid molecules to deliver nucleic acids encoding U7-based snRNAs to induce exon-skipping for use in treating a muscular dystrophy including, but not limited to, DMD, resulting from a mutation amenable to skipping exon 44 of the DMD gene (DMD exon 44) including, but not limited to, any mutation involving, surrounding, or affecting DMD exon 44.

Abstract: The present invention relates to the delivery of oligomers for treating patients with a 5? mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5? mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.

Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.

Abstract: The present invention relates to the delivery of oligomers for treating patients with a 5? mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5? mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.

Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.

Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.

Abstract: The present invention relates to the delivery of oligomers for treating patients with a 5? mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5? mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.

Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.

Abstract: A buffer accessible by an application executing under an application server in a first address space is managed by a database adapter executing in a second address space. A data request from the application executing in said first address space, comprising a buffer locator in the empty state, is received by the database adapter executing in the second address space. A buffer is allocated in the first address space and the address of this buffer is stored in the buffer locator. Data associated with the data request, received from a database subsystem, is copied to the buffer. Control is then transferred back to the application whereby the application utilizes the buffer locator to access the buffer and process the data contained therein. A database adapter automatically managing application buffers across address spaces in accordance with the present invention may be referred to as an “auto-buffer database adapter”.

Abstract: Disclosed is a Single Condition Amplification/Internal Primer (SCAIP) sequencing method which allows for the rapid, accurate, and economical analysis of any large multi-exon gene. The method can be used to detect genomic mutations in any large multi-exon gene including the dystrophin gene. In some forms, the method can rely on amplification of a large number of exons at a single set of PCR temperatures with a first set of amplification primers followed by sequencing without optimization of individual amplicon conditions, using a second, internal set of sequencing primers. The SCAIP method provides for the identification and analysis of specific individual genomic mutations such as deletions, point mutations, frameshifts, or combinations thereof, in gene complexes with multiple exons/introns spanning large genomic regions.

Abstract: A buffer accessible by an application executing under an application server in a first address space is managed by a database adapter executing in a second address space. A data request from the application executing in said first address space, comprising a buffer locator in the empty state, is received by the database adapter executing in the second address space. A buffer is allocated in the first address space and the address of this buffer is stored in the buffer locator. Data associated with the data request, received from a database subsystem, is copied to the buffer. Control is then transferred back to the application whereby the application utilizes the buffer locator to access the buffer and process the data contained therein.

Abstract: A method, apparatus, and article of manufacture for generating program specifications for a computer program that accesses datastore persistent objects materialized from a datastore. A "wizard" or "task guide" is displayed on a monitor attached to a computer, wherein the wizard comprises a step-by-step procedure for creating the program specifications. Operator input is accepted into the computer in response to the step-by-step procedure and the program specifications are created using the operator input.